Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels

Channel Catalog

Channel Description:

ACN Newswire press release news - Recent Press Releases

older | 1 | .... | 266 | 267 | (Page 268) | 269 | 270 | .... | 320 | newer

    0 0

    Rally Italia Sardegna: Preview

    TOKYO, Jun 1, 2018 - (JCN Newswire) - Rally Italia Sardegna represents the halfway point of the 2018 FIA World Rally Championship season, as round seven out of 13. The TOYOTA GAZOO Racing World Rally Team will again be aiming for a top result on the Italian island event with its Yaris WRCs driven by Jari-Matti Latvala, Ott Tanak and Esapekka Lappi.

    Rally Italia Sardegna is characterised by fast but narrow gravel roads, which are lined by trees and rocks, leaving very little margin for error. The fine sandy surface is gradually swept away by each passing car, exposing the harder, rocky base underneath. High temperatures can stress the crews and their cars.

    The event will begin on Thursday evening with a super special stage at Ittiri near the rally base in Alghero. Friday consists of four stages to the north-east which will all be run twice, while on Saturday there will be two loops of three stages in the Monte Acuto region, separated by another visit to Ittiri. The rally concludes on Sunday with two repeated stages north of Alghero.


    Tommi Makinen (Team Principal)
    "I am feeling confident about we can achieve in Sardinia. We had a very good test there before Rally Argentina, which was of course a great event for us. I believe that we should have a strong package for these kind of roads. Generally, the performance has been very positive over the past few rallies, and everybody in the team is working hard to keep improving. We already had some good results in Sardinia last year, and Ott won the rally, so I think it is an event where all of our drivers feel comfortable. Overall, there are many reasons to be positive."

    Jari-Matti Latvala (Driver car 7)
    "I always enjoy competing in Sardinia. I actually drove there for the first time in 2003 on the Rally Costa Smeralda, the year before the WRC started going there. The roads have a very hard base with a layer of sand on the top which can make it very slippery for the first cars on the road. The roads are narrow but you can go very fast if you can keep to the right line. I feel positive heading to Sardinia. I had two clean days of driving in Portugal without any mistakes and this helped my confidence a lot, and I am really enjoying driving this car."

    Ott Tanak (Driver car 8)
    "Sardinia is a special rally for me as it's where I got my first win one year ago. Hopefully we can get another top result this time around. I think this will be a key rally for the championship. Portugal obviously didn't go as well as we planned or hoped, so it will be really important to score some strong points. We are trying to be well prepared as possible, and I know that the team is working really hard. I am really happy with how the car has been performing: In Argentina it was fantastic and it felt good in Portugal as well. Now we just need to translate that speed into a good result before the summer holidays."

    Esapekka Lappi (Driver car 9)
    "I am really looking forward to competing in Sardinia again. We had a pretty good result there already last year and my speed was good, as we won six stages. I think I have learnt a lot since then, and there has also been a lot of progress with the car. I have felt very comfortable over the last couple of rallies and I have had the confidence to push hard. Now that we are fifth in the championship, we will have to run quite early on the road on Friday. The road cleaning effect can be quite big there, but I got some good experience of this on the final two days in Portugal, so I am not worrying about this too much."

    What happened last year?

    Toyota enjoyed a strong first visit to Rally Italia Sardegna. Jari-Matti Latvala finished in second place (close behind his future team-mate Ott Tanak, who won the rally) while Esapekka Lappi was fourth in only his second event at the highest level of the WRC, posting six fastest times including on the Power Stage. Juho Hanninen also won a stage on his way to sixth overall.

    About Toyota

    Toyota Motor Corporation (TMC) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 29 countries, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries under the brands Toyota, Lexus, Daihatsu and Hino. For more information, please visit

    Public Affairs Division Global Communications Department Toyota Motor Corporation Tel: +81-3-3817-9926

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    HONG KONG, Jun 2, 2018 - (ACN Newswire) - According to an article published on Gelonghui on 16 May, 2018, commercial factoring is the most efficient financing channel for the development of SMEs which is regarded as an important driving force for the future growth of China's economy. At present, commercial factoring business is mainly based on offline acquisition channel. However, the combination of both online and offline customer acquisition will be the future trend. This is especially true for SMEs, whose small and fragmented financing services can be more efficiently addressed by online channel.

    Supportive policy for SME financing

    SMEs are the key driving force of innovation and entrepreneurship in China. Nowadays, SMEs face a large financing gap as most of their financing needs have yet to be satisfied by traditional banking channels. On the contrary, non-bank financing channels possess more advantages and flexibility. In recent years, thanks to the supportive regulatory policies, the non-bank financing business has grown rapidly, with more diverse business models including trust, commercial factoring and financial leasing.

    Among these non-bank financing channels, commercial factoring is one of the fastest growing channels. The main reason behind is that commercial factoring places emphasis on credit assessment on repayment of the buyer company, and therefore help SMEs to overcome the financing barriers due to lack of collateral and low credit rating.

    What is factoring service? What can factoring service providers do?

    Factoring service is a method of supply chain finance service based on accounts receivable, and its core function is to provide financing. A company may provide financing to a seller who sells accounts receivable through factoring so as to charge interest and handling fees and transfer the receivables to the company. In order to make it easier for SMEs to obtain financing at an affordable price, it is particularly important for the supply chain financing providers to ensure the authenticity of underlying transactions. To encourage supply chain financing, the Chinese government has rolled out a number of supportive policies in recent years.

    Factoring assets are high-quality investment assets with relatively low risks and high returns. It is expected that various types of participants such as large financial institutions, large-scale buyer companies and independent commercial factoring providers will gradually increase their investment of the commercial factoring assets.

    New economy and new model: O2O is now the dominant trend and online commercial factoring is emerging

    With the development of financial technology in China, the commercial factoring industry is also increasingly dependent on digital technology. With the assistance of technology, commercial factors are capable of using online platforms for fund sourcing, and conducting big data analysis for effective risk control.

    In addition, online commercial factoring also has the following advantages:

    (1) Overcoming information asymmetry: Online factoring platform can be used by a large number of potential borrowers, on which they can register their funding needs. Commercial factoring can have easy access to this kind of information, therefore optimizing the source of assets and expanding asset pools.

    (2) Online electronic process: The transaction data collected by the online factoring platform can be subject to centralized and automated processing in order to reduce labor costs and improve the efficiency of new financing.

    (3) Market efficiency: Online factoring platform can resolve the information asymmetry between capital supply and demand and match funds with assets, thus creating an efficient market for both parties to identify the optimized risk-pricing for factoring assets.

    (4) The cost of factoring is lower: Online factoring platform creates a free competitive market, enabling SME asset suppliers to maintain their bargaining power so that they can request for a fair price upon renewal of factoring contracts. At the same time, the digitalized platform can store corporate data of the SMEs, eliminating the need for duplicated submission of documents and risk assessment processes.

    However, if a commercial factoring company has to establish a commercial factoring business with an O2O model, it should possess professional technical and risk control abilities. Besides, sufficient capital for market making would be also fundamental in order to improve the success rate of matching up factoring needs and enhance the activeness of the platform.

    Introduction of Vteam Financial Services Group

    Vteam Financial Services Group ("VTeam"), a financial technology company invested by Softbank, is a supply chain financial service platform company with strong technical ability and in-depth understanding of the factoring market. Unlike P2P platforms, VTeam is a licensed company that is qualified to engage in commercial factoring and has operated in supply chain finance business for more than 16 years.

    Softbank became one of the substantial shareholders of VTeam in 2011. Since then, Softbank has provided support and resources to VTeam in its expansion in the Chinese market. As a sophisticated investor, especially in the technology, media and telecommunication sector, Softbank offers strategic guidance to the development of the technology business of VTeam, laying a foundation for the success of its business.

    VTeam's technology hub, Ju Ying Jin Lian, together with its technology-driven online platform that is connected to the hub, is the only open and independent online trading platform focusing on factoring financing among China's top five online factoring platforms (based on the 2017 total transaction volume).

    VTeam has submitted A1 prospectus to the Hong Kong Stock Exchange. Its net profit in 2017 exceeded RMB195 million. Investors who have been keeping a close eye on Softbank's investment, or those who aspire to develop their career in the commercial factoring industry, should pay close attention to this industry leader against the backdrop of "Internet + Finance".

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    HONG KONG, June 2, 2018 - (ACN Newswire) - Blockpass, the blockchain-based identity application which gives users total control over their own personal data, is pleased to announce the launch of its Initial Token Distribution Event (“TDE”) through the sale of tokens (“PASS tokens”) which will be available for purchase from official distributors from 31st May 2018 until 30th November 2018.

    • Blockpass is an identity application for regulated services and the Internet of Things (IoT).  As a self-sovereign identity platform, users can establish, verify, store and manage their identities, maintaining full control over all data involved.
    • With an initial focus on human identity, Blockpass will provide a reliable and cost-effective Know-Your-Customer (“KYC”) and Anti-Money-Laundering (“AML”) service for regulated industries, blockchain merchants and service providers.
    • Available on iOS and Android, the Blockpass app is consumer-oriented and will enable users to create a new account (profile), submit documents for verification, submit their digital identity to service providers to pass KYC, log in to Blockpass-enabled services, sign crypto-asset transactions, and access third-party decentralized applications (“Dapps”).
    • Blockpass has published its White Paper which can be found on the Company’s website at
    • The PASS token will be an ERC20-based token
    • Blockpass will issue a finite number of 1 billion PASS tokens of which 250 million PASS tokens will be available for purchase during the Initial TDE from authorised distributors
    • The PASS tokens available at the Initial TDE will be priced at 0.08 Euro per PASS token

    Adam Vaziri, CEO of Blockpass, said: “Blockpass provides an exciting, easy to use, identity verification solution to the proliferating and serious security challenges created by the fast-evolving digital age. By turning personal validation data into an anonymous cryptographic code that is whitelisted on the blockchain, Blockpass gives users back control over their own identities and eliminates the need for painful online validation processes.  Businesses will benefit from vastly reduced KYC/AML costs and will no longer have the liability of protecting vast amounts of sensitive personal data in an age of GDPR.

    Today represents an exciting milestone for Blockpass as it will allow us to accelerate the development of a differentiated offering that will bring transparency and trust to the blockchain ecosystem where we are already established with a dozen leading suppliers and partner companies.  We have an experienced management team with a clear revenue model and strategy for growth and a first mover, patented advantage in the growing regtech market which is expected to reach $118.7 billion USD by 2020.  The funds generated from the PASS tokens accelerate awareness through branding and marketing and the tokens themselves will be used to encourage utilisation.  Holders of the PASS tokens will also participate in the growing value of Blockpass.   

    We have numerous opportunities for growth but are prioritising crypto offerings and financial services where the need for identity validation is particularly acute.”


    Adam Vaziri, CEO

    Hans Lombardo, CMO


    Tel: +852 9688 1719


    Buchanan (UK Financial PR)

    Alex Brown / Chris Lane / Jamie Hooper / Olivia Montefiore-Vita

    Tel: +44 (0)20 7466 5000


    The Blockpass Human Identity Solution

    Blockpass manifests itself as a user-centric and self-sovereign identity application for regulated services and the Internet of Things. Blockpass offers a next-generation, effective identity creation and storage protocol.

    Blockpass is built with self-sovereignty in mind: Blockpass starts from the premise that users need to hold and control their own identifying data - not third parties. So, in Blockpass, online identity data belongs to, and is entirely controlled by, the user. Blockpass does not retain any user data, nor is any raw user data stored on any blockchain - only hashes. Users choose what credentials they want to have verified and signed (such as a proof of address or a government-issued piece of ID), decide where that data is stored (such as on their device or in the cloud), and control who may see it.

    Blockpass digital identities have a high degree of utility: As an owner of a Blockpass verified identity, you gain access to a growing ecosystem of Web 3.0 service providers that have chosen to accept Blockpass identities as KYC. For businesses, Blockpass can be seen as a shared KYC platform, where a pool of pre-verified users is shared between businesses thus reducing the cost and time of onboarding new customers.

    Blockpass digital identities are underpinned by their reusability: With a Blockpass identity application, the user keeps all their digital KYC in a single place, which they have at their fingertips at any time. Once the user’s credentials have been verified and signed, they may re-use them quickly and simply with any number of services. When a user joins a new regulated service, if their Blockpass identity application is configured, they can prove their identity extremely quickly.

    Blockpass offers an onchain identity solution that is easy to combine with other decentralized technologies or processes: Blockpass offers an onchain, immediately available, verified digital identity. For a transaction to be compliant in regulators’ eyes, both transacting parties need to prove the transaction was personally authenticated. With Blockpass, users can transparently sign transactions and Dapp accounts with their compliant digital identity, meaning that buyers and sellers will be able to safely and compliantly complete transactions and that Dapps will seamlessly meet the basic verification requirements for the services they provide. Furthermore, this setup enables the generation of multi-signature smart contracts that require personal authentication with the Blockpass tool.

    Blockpass meets GDPR requirements: On 25th May 2018, the General Data Protection Regulation (“GDPR”) went into effect in the European Union. As a user-centric identity application, Blockpass meets GDPR requirements. Blockpass and its suite of products are perfectly situated to enable blockchain business operations in the second largest economy in the world, in addition to other regions.

    Benefits for Businesses and Individuals


    A comprehensive identity verification portal for quick and easy user onboarding for regulated industries.

    1. Rapid User Onboarding: The use of blockchain technology and smart contracts eliminates tedious KYC & AML compliance procedures by reducing sign up friction and increasing conversions.

    2. Low Cost Pre-verified Compliance: With shared regulatory and compliance services, it becomes possible to onboard users without expensive and duplicative identity verification of the same user multiple times across different services.

    3. New Application Potential: A modernized compliance protocol will enable new levels of efficiency and application possibilities for blockchain, fintech, and traditional institutions.


    A faster, safer, easier way to access regulated industries.

    1. Speedy Gateway to Compliant Services: Blockpass provides a secure and rapid gateway to access ICOs, exchanges, and other regulated services without the need to complete redundant compliance requirements.

    2. Own your own Data: Blockpass is a self-sovereign identity verification service that only stores a cryptographic representation of your verified identity on a blockchain whitelist. Your data is stored on your mobile device and shared only with those who you choose.

    3. Shared Identity Whitelist: The end of multiple KYC identity checks. Blockpass enables users to get approved and whitelisted once for near immediate access to multiple merchants and service providers.

    Market Drivers

    Self-sovereignty is something people want:

    In a study carried out by the Pew Research Centre, 91% of respondents agreed that consumers have lost control over how personal information is collected and used by companies. Decentralized KYC gives users full-control over their data, and this is something people want and are willing to pay for.

    Decentralized KYC means more cost-efficiency for businesses:

    KYC solutions are prohibitively expensive. In a report, Consult Hyperion estimated that a KYC check can cost 10 to 100 GBP (11 to 114 euros) per customer.  In the most extreme example, Thomson-Reuters found that some firms were spending up to 500 million USD (400 million euros) on KYC compliance and customer due diligence. Simply by eliminating data storage costs, decentralized KYC can prove to be cost-efficient to businesses.

    Decentralization fosters a better user experience:

    Centralized data storage means that a KYC check likely only applies to a single onboarding process. Decentralized data storage enables the possibility of a universal identity gateway. With the Blockpass Identity application, the user keeps all their digital KYC in a single place - on their personal device - which they have at their fingertips at any time. Once the user’s credentials have been verified and signed, they may re-use them quickly and simply with any number of services. When a user joins a new regulated service, if their Blockpass identity application is configured, they can prove their identity extremely quickly.

    Web 3.0 developers demand decentralized KYC for their products:

    Current online identity services cannot support the burgeoning development of Dapps and crypto-assets. KYC solutions that operate off-chain cannot reconcile users’ digital identities with decentralized applications. Blockchain Dapps currently lack regtech solutions that would enable compliant and secure services. For Dapps to reach their full potential - to be compatible with regulated transactions - they require a method to verify user identities.

    Crypto-asset transactions require onchain KYC:

    Security tokens, which are currently being issued as ‘meta’ tokens on Ethereum, Neo, and other networks, require KYC of the issuer, sender, and receiver of the asset. Transactions of the assets should be irreversible from a legal and non-technical point of view, which is only possible by proving that the counterparty actually signed a transfer with Blockpass. Additional AML laws are increasingly being enforced for crypto transactions.

    Using the Blockpass Identity to Access Services

    Within the application, services can be found in the “Services” menu. Services that are listed on the app are listed according to the amount of KYC that is required for user onboarding. Services for which the user has provided enough information to onboard are listed first, while ones for which the user must provide more information are listed later.

    Alternatively, services can be accessed through the use of a QR code. Upon scanning a code, Blockpass prompts the user to submit the necessary profile information to access that service.

    Service providers may perform additional verification checks before onboarding the user. In some cases, the service provider can issue certificates that the user can choose to add to their profile.

    Blockpass Identity Backup and Recovery

    It is possible for Blockpass users to backup their identity. As Blockpass is a user-centric solution, the backup process can only be initiated manually - at the request of the user. Backups contain all user-generated content, certificates, and the local key. The backup manifests itself as a binary file, which is encrypted with a password. In version one of the Blockpass user app, users may send the backup file to their email. Other destinations will be integrated in future releases. When a user wishes to recover their identity, they port it into the app that is downloaded to their app by connecting the email address that holds the backup file and entering a pin.

    For more information and updates, please visit and sign up to the following:

    Promotional video:

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Global Leader in Business Risk Intelligence (BRI) provides Decision Advantage over Threats and Adversaries

    SINGAPORE, Jun 4, 2018 - (ACN Newswire) - Flashpoint, the global leader in Business Risk Intelligence (BRI) from the Deep & Dark Web (DDW), has officially announced its expansion in the Asia-Pacific market, with significant focus on Singapore, Japan and Australia.

    Jankang Tao, whose appointment as Flashpoint Managing Director for Asia-Pacific at follows 16 years leading business initiatives for global organisations such as Internet Security Systems, IBM, JouleX and Cisco, will oversee operations in the region.

    The company's decision to strengthen its presence in Asia-Pacific follows its roadmap. Home to global leaders in industries such as technology, oil and gas, manufacturing, retail, and financial services, Asia-Pacific is an ideal environment for Flashpoint to pursue its mission.

    However, as markets and business practices in Asia-Pacific continue to evolve, so do the threats and adversaries that organisations in the region are facing. Flashpoint analysts have been monitoring several cybercrime trends specifically in relation to the region's core industries, including:

    - Law enforcement action against criminal Bitcoin exchanges and tumbler services
    - Cybercriminal groups increasingly seeking and recruiting insiders in financial institutions
    - The apparent adoption of financially motivated cybercrime techniques (ransomware and attacks on financial institutions for profit)
    - Consistent discussions of, and recruitment for, insider trading schemes leveraging data stolen from financial institutions, news agencies, and law firms

    Flashpoint's offerings are particularly suitable for the region. With unique DDW data, expertise and technology, the company's BRI empowers organisations with a decision advantage over threats and adversaries. By broadening the scope of intelligence beyond threat detection, BRI provides relevant context to business units not traditionally afforded the benefits of intelligence derived from the Deep & Dark Web.

    "We are excited to be ramping up our presence in Asia-Pacific. Not only will this expansion provide Flashpoint with ample opportunity to partner and collaborate with leading experts in the region, it will enable us to provide even more organisations with a decision advantage over a broad spectrum of threats and adversaries," said Josh Lefkowitz, Flashpoint CEO and co-founder.

    "Flashpoint's expansion in Asia-Pacific presents a fantastic opportunity for even more organisations to develop and enhance their security and risk postures with BRI," said Jankang Tao. "I am excited to collaborate with esteemed experts in all sectors throughout the region, to combat insider threats, fight fraud and mitigate third-party risk, among many other use cases."

    A forward-looking assessment of the 2018 geopolitical landscape, the Flashpoint BRI Decision Report is at or request a meeting at

    About Flashpoint
    Flashpoint delivers Business Risk Intelligence (BRI) to empower business units and functions across organisations with a decision advantage over potential threats and adversaries.

    The company's sophisticated technology and human-powered analysis enable enterprises and public sector organisations globally to bolster cybersecurity, confront fraud, detect insider threats, enhance physical security, assess M&A opportunities, and address vendor risk and supply chain integrity.

    NYC-based Flashpoint is backed by Georgian Partners, Greycroft Partners, TechOperators, K2 Intelligence, Jump Capital, Leaders Fund, Bloomberg Beta, and Cisco Investments. Visit

    Media Contact:
    PRecious Comms for Flashpoint
    Tan Yanchang
    Tel: +65 6303 0567 Ext 1001

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    PERTH, W. AUSTRALIA, Jun 4, 2018 - (ACN Newswire) - Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States, creating a partnership with US-based precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx ).

    Proteomics International has granted PHDx, head-quartered in Austin, Texas, a licence for the clinical market in the USA to make PromarkerD available to the more than 30 million Americans living with diabetes. Commercial details for the licensing agreement remain confidential.

    The USA has one of the highest rates of diabetes in the world and is by far the biggest spending country on diabetes-related healthcare. Kidney disease is responsible for 48,000 deaths a year in the USA - the ninth leading cause of death - and related healthcare spending tops US$50 billion a year.

    Dialysis treatment alone costs US$72,000 per person per year, according to the US Renal Data System. Diabetes accounts for 44% of chronic kidney disease cases in the USA.

    Proteomics International Managing Director Dr Richard Lipscombe said PromarkerD was a major weapon in the battle against the diabetes epidemic. "Regular testing and early diagnosis of diabetic kidney disease with PromarkerD can help millions of people avoid costly and invasive dialysis treatment or a kidney transplant," he said.

    "We are very excited to launch this product nationally across the USA," said Jim Canfield, President and CEO of PHDx. "This revolutionary technology will complement PHDx's existing portfolio to create the leading diabetes test offering in the country. It will save lives and improve the quality of life for diabetes sufferers, all while reducing the cost to the healthcare system."

    Under the licence agreement PHDx will develop and commercialise the PromarkerD mass spectrometry "Laboratory Developed Test" (LDT) in its specialist certified laboratories. The LDT permits fast adoption of a new test in advanced markets.

    PromarkerD is a simple blood test that uses a unique protein 'fingerprint' to detect signs of disease. PromarkerD is the first test able to predict the onset of diabetic kidney disease, warning of a decline in kidney function up to four years in advance. The test can also diagnose diabetic kidney disease better than the current gold standard tests.

    PromarkerD has the potential to spare millions of people from future dialysis costs, and save the US healthcare system hundreds of billions of dollars.

    For every million people living with diabetes, 10% - or 100,000 people - are expected to suffer a rapid decline in kidney function within the next four years. The PromarkerD test is able to predict this decline in kidney function in 86% of cases. This means that if every one of the 30 million Americans with diabetes took the test it would potentially identify 2.6 million of the 3 million people on the path to kidney disease.

    Those identified would require systematic retesting to verify effectiveness of treatments. Another 84 million American adults - more than 1 out of 3 - have prediabetes, a precursor to diabetes, and may also benefit from taking the PromarkerD test.

    Dr Lipscombe said the breakthrough deal for PromarkerD in the USA is important because it paves the way for other licensing contracts. "It is great to see PromarkerD launching in the world's largest healthcare market as we further negotiations to commercialise the test in other countries including Mexico, Japan, Australia, China and Europe."

    About PromarkerD (
    PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years.

    PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe and Japan, with others pending. Further information is available through the PromarkerD web portal.

    About PHDx, Inc (
    PrismHealthDx, Inc. (PHDx) is a precision medicine diagnostic laboratory and services company specialising in comprehensive biomarker testing to detect the onset of disease and serious medical conditions at their earliest and most treatable stage. PHDx provides a 'one-stop-shop' opportunity to integrate best-in-class laboratory and clinical medicine into practices, driving better clinical outcomes and helping to make an immediate difference in the lives of their patients.

    PHDx's management team has extensive experience in developing and commercialising novel assays and they are committed to advancing new diagnostic and disease management capabilities. PHDx works in partnership with academic leaders, industry leaders, and clinical providers.

    About Proteomics International Laboratories (PILL)
    Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on Perth's QEII Medical Campus. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

    Medical Contact:
    Chuck Morrison
    Head of Business Development
    Proteomics International
    T: +1 617 331 2975

    Jim Canfield
    President & CEO
    PrismHealthDx, Inc. (PHDx )
    T: +1 770 335 0334

    Media Contact:
    Susan Fitzpatrick-Napier
    Digital Mantra Group
    T: +1 650 798 5238
    T: +61 2 8218 2144

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Management of Tonghai Financial Group, including Mr. Richard Winter, Senior Advisor of Tonghai Financial Group (seventh from left), Mr. Chris Wu, Chief Financial Officer of Tonghai Financial Group, (sixth from left), Mr. Army Yan, Chief Investment Officer of Tonghai Financial Group, (sixth from right), took picture together with award presenters and representatives of awarded companies.
    In recognition of excellence of 15 listed companies, widely supported by the business community and media of Hong Kong and China

    HONG KONG, Jun 4, 2018 - (ACN Newswire) - The award presentation ceremony of Quam IR Awards 2017 (QIRA) successfully took place on 30 May, 2018 at Four Seasons Hotel Hong Kong. Eminent representatives of listed companies from different sectors supported the event, sharing the valuable experience in Investor Relations achievements. The event was widely supported by the business community and elites of different industry, creating an unprecedentedly grand occasion.

    Quam IR Awards steps into its third year, recognizing excellence in Investor Relations
    Quam IR Awards was established in 2016. In the past three years, it dedicated to honoring models of practice and leadership in Investor Relations (IR) among the listed companies in the Asia Pacific region. Winners have been devoted in upholding transparent communications between companies and stakeholders throughout 2017. The Quam IR Awards serves as the well-recognized testimonials to the winners' excellence, which can help bring accreditation and prestige to the winning companies and their remarkable achievement in the area of IR among shareholders, institutional investors, equity research analysts and financial media.

    Awarded companies in Quam IR Awards 2017 come from various categories, ranging from Hang Seng Index Constituents, Main Board and First Year After Listing companies, representing multi-national enterprises to local companies. A total of 15 awards were presented, the winners include Bank of China Limited, Bar Pacific Group Holdings Limited, Carnival Group International Holdings Limited, China LotSynergy Holdings Limited, China Resources Power Holdings Company Limited, Cosmos Machinery Enterprises Limited, Dah Chong Hong Holdings Limited, Guotai Junan International Holdings Limited, Hengan International Group Company Limited, Huazhang Technology Holding Limited, Li & Fung Limited, New World Development Company Limited, Plover Bay Technologies Limited, Shui On Land Limited and Yuexiu Real Estate Investment Trust. Among the awarded companies, Bank of China Limited, Li & Fung Limited, New World Development Company Limited and Shui On Land Limited have been awarded continuously for three years.

    Business elites and figures supported the event
    At the ceremony, Mr. Army Yan, Chief Investment Officer of Tonghai Financial Group, said "awarded companies demonstrate the multiplicity, dynamics, outstanding corporate governance and culture of the business community of Hong Kong. Together with these important elements, it enhances Hong Kong's status as International Financial Center, meanwhile, it brings additional economic activities to the capital markets." Mr. Chris Wu, Chief Financial Officer of Tonghai Financial Group, said "we are happy to meet some old friends this year again, and we warmly welcome new friends to the Awards. Your determination in upholding high standards of corporate governance will be role models of other listed companies. As Hong Kong's listing regime enters its new era, we look forward to seeing a more diversified development, with innovation and dynamics, in the exchange markets of Hong Kong."

    Oceanwide IR was honored to invite Mr. Anthony Fan, President of The Hong Kong Independent Non-Executive Director Association; Mr. Stephen Ho, Chief Executive of Society of Registered Financial Planners; Mr. Jerry Hu, Chairman of Federation Economic and Commerce of Hong Kong; Ms. Lee Sai Yin Jeanne, JP, Chairman of the Hong Kong Securities Professionals Association; Dr. Christopher To, Deputy Chairman of The Hong Kong Institute of Directors, as our guests of honor to witness the glorification of the listed companies demonstrated IR excellence.

    Mr. Anthony Fan said, "investors relations play a vital role in the success and growth of a company, business community has been paying more attention to the work of investor relations throughout the years. The Awards is set out to raise awareness of outstanding investors relations of listed companies in Hong Kong, setting a standard in the recognition of excellent performance on information disclosure and corporate development." Mr. Stephen Ho said investors are eager to find value in financial reports and statements, the awarded companies this year have demonstrated excellent incorporation of financial information, corporate development and sustainable development. While providing all-rounded information for investors and the public, it certainly upholds the transparency of the company and the business environment.

    Mr. Jerry Hu is glad to witness the awarded companies this year are dedicated to enhancing excellent enterprise reputation and credibility through all-rounded investor relations services, providing timely and updated information, great interaction with investors and promoting healthy corporate culture.

    Ms. Lee Sai Yin Jeanne, JP said awarded companies strived to deliver exceptional investor relations practices and commitment to the investors and shareholders, channeling appropriate financial reporting, market disclosures and information in a professional manner. The contributions were remarkable and extraordinary.

    Dr. Christopher To stated that, despite the ever-changing business environment, the awarded companies this year have strived to serve the interests of their organizations and shareholders. Management and IR professionals have been engaging with shareholders in different ways with effective communication and conscious effort.

    Unfailing support from media & sponsors
    Apart from the support of notable guests, the award presentation ceremony attracted numerous media and sponsors in Hong Kong and China. Our supporting media partners include Metro Daily, The Standard,, FX678, OTCbeta, PEdaily, p5w, and SLTopnews. Besides, several companies supported QIRA by offering products & prize sponsorship, namely FX Creations International Limited, Impact Originals, Canon Hongkong Company Limited, HKTaxi App, Catalo and Tsit Wing Coffee.

    Key to success of winning listed companies

    BOC enhances communication with investors from China and Hong Kong
    Mr. Tommy Mok, Senior IR Manager of Bank of China (Hong Kong) Limited, stated that Bank of China Limited as the A+H dual listed company, has long been upholding the close interaction with investors from China and Hong Kong. In the past year, the company has been introducing the strategy and business development to overseas investors through various IR activities, meanwhile it has been utilizing different channels, enabling investors to obtain the latest information and it is widely recognized. In the future, the company will be accelerating and persevering in the communication with investors.

    Cosmos Machinery builds relationships with different channels
    Mr. Freeman Tang, Executive Director & CEO of Cosmos Machinery Enterprises Limited, stated that the company was founded in 1958. After half a century's development, Cosmos' business has diversified rapidly and now covers different areas. Cosmos Machinery develops its own expertise in construction and application, strives to become an innovative and responsive enterprise and thus creates greater values for stakeholders. Celebrating its 60th Anniversary in 2018, Cosmos Machinery, to keep abreast of times, is determined to implement digitalization, transformation and integration, automation in manufacturing. Meanwhile it will enhance communication with shareholders and investment community to uphold outstanding corporate governance.

    Dah Chong Hong values Investor Relations
    Ms Gwen Walters, Head of Corporate Communications and Investor Relations of Dah Chong Hong Holdings Limited, shared "This year, we committed a great deal of effort towards enhancing our IR to better engage our investors through roadshows, meetings and even company visits. Furthermore, we also enhanced our reporting of ESG practices to better share our commitment to build sustainable value for shareholders towards the investment community."

    Hengan International actively communicates with markets
    Mr. Martin Li, Executive Director & Deputy CFO of Hengan International Group Company Limited, stated that Hengan Group implemented the nation-wide operating model "small sales team" in recent years and successfully vitalized the sales network. Apart from sufficient information disclosures, Hengan's professional IR team strengthens communication and interaction with investors, elevates transparency in diversified ways of communication. Hengan will keep actively communicating with the market, ensuring latest development is delivered to the market by ensuring the interaction between investors and shareholders.

    Huazhang strives to uphold the transparency
    Mr. Zhu Gen Rong, Chairman of Huazhang Technology, said, "We are delighted that the Group has received this award , which is a kind of recognition of the Company's outstanding performance in investor relations . Looking forward, we will continue to improve corporate transparency and consolidate investors' confidence in us . We will also explore creative formats to disclose information, so that our investors better understand and receive up to date information about the Group's updates . The Group will make efforts to improve our investor relations, with synergies from business development, to maximize shareholders' return."

    New World Development creates values with the Artisanal Movement
    Mr. Aldous Chiu, General Manager-Strategy and Investor Relations of New World Development Company Limited, described NWD as the premium brand infused with a unique personality defined by The Artisanal Movement. The Group endeavors to maintain a high standard of corporate disclosures in compliance with the legal and regulatory requirements and believes that delivery of clear messages regarding the group's strategy, business development and prospect will enhance and create value for stakeholders.

    The list of awardees for Quam IR Awards 2017 (in alphabetical order of company name):

    Company Name Award - Category
    1. Bank of China Limited (Stock Code: 3988) - Hong Kong Index Constituents(Hang Seng Index) Category
    2. Bar Pacific Group Holdings Limited (Stock Code: 8432) - First Year After Listing Category
    3. Carnival Group International Holdings Limited(Stock Code: 996) - Main Board Category
    4. China LotSynergy Holdings Limited (Stock Code: 1371) - Main Board Category
    5. China Resources Power Holdings Company Limited (Stock Code: 836) - Hong Kong Index Constituents (Hang Seng Index) Category
    6. Cosmos Machinery Enterprises Limited (Stock Code: 118) - Main Board Category
    7. Dah Chong Hong Holdings Limited (Stock Code: 1828) - Main Board Category
    8. Guotai Junan International Holdings Limited (Stock Code: 1788) - Main Board Category
    9. Hengan International Group Company Limited (Stock Code: 1044) - Hong Kong Index Constituents (Hang Seng Index) Category
    10. Huazhang Technology Holding Limited (Stock Code: 1673) - Main Board Category
    11. Li & Fung Limited (Stock Code: 494) - Main Board Category
    12. New World Development Company Limited (Stock Code: 17) - Hong Kong Index Constituents (Hang Seng Index) Category
    13. Plover Bay Technologies Limited (Stock Code: 1523) - Main Board Category
    14. Shui On Land Limited (Stock Code: 272) - Main Board Category
    15. Yuexiu Real Estate Investment Trust (Stock Code: 405) - Main Board Category

    Website of Quam IR Awards 2017:

    For enquiries,
    Oceanwide IR
    Marketing & PR contact:
    Jane Chan T: 2217-2906 Email:
    Stella Yuen T: 2217-2908 Email:
    Nicola Lung T: 2217-2909 Email:

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Gravity - a blockchain protocol based on Graphene, offering open-source frameworks for SME - implements the pioneering Delegated Proof-of-Importance (DPoI) consensus algorithm for small and medium-sized enterprises

    HONG KONG, Jun 4, 2018 - (ACN Newswire) - Gravity Solutions, the blockchain research and development firm, has announced the launch of its public testnet for the Gravity protocol that is poised to power next-generation distributed ledger solutions for small and medium-sized enterprises. According to the development team, the protocol offers a visionary take on network architecture and implements the Delegated Proof-of-Importance (DPoI) consensus algorithm. Inspired by Graphene - the open-source, modular blockchain framework - Gravity aims to incentivize the creation of decentralized organizations, small businesses, and applications while offering a mechanism for rewarding all network participants.

    CEO and Co-founder of Gravity Solutions, Yury Parsamov, said, "Gravity aims to operate on two levels: protocol and solutions.

    Gravity Protocol's core features (the pioneering Delegated Proof-of-Importance (DPoI) consensus algorithm and a proprietary Index of Importance) incentivizes active network participants directly and thus stimulates network growth. Unlike other consensus algorithms (POW, POS, DPOS) the inflational emission is distributed not among the passive network users (miners, block producers, high stake holders), but among the most active ones and this ables Gravity Protocol to become a really used blockchain."

    "On solutions level we build frameworks for small and medium enterprises, which is also a new approach within the industry of blockchain R&D, which is so fat heavily focused on offering solutions for governments, banks and corporations"," added Parsamov.

    The Gravity Index, or the Index of Importance, takes into account such factors as: account's stake, number of incoming transactions, account's position in network's cluster, cluster activity and lot of other parameters, described in Gravity's architecture paper.

    Unlike other blockchain protocols, emission happens only when the network grows in terms of new accounts, volume of transactions and connections within the network.

    To date, Gravity Solutions has successfully completed deployment of the private testnet to ensure the correct, secure and decentralized token distribution powered by the Gravity protocol and the Index of Importance. With the launch of the public testnet, open to all developers and Graphene enthusiasts, the blockchain R&D firm has allocated 10% of the initial ZGV token supply to reward participants for their contributions and feedback. The testnet stage will conclude on June 20, 2018.

    For more information about Gravity protocol please visit:
    High-res photo:

    About Gravity Solutions
    Gravity Solutions is a blockchain research and development firm that aims to create a transparent, efficient and flexible framework for Small and Medium Enterprises. According to the development team, the Gravity protocol implements the pioneering Delegated Proof-of-Importance (DPoI) consensus algorithm to ensure the fair-minded distribution of tokens to incentivize network participants.

    Media Contact:
    Across Asia Communications Limited
    Kent Lau
    Phone: +852 3111 5199

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Contributes to Improving Efficiency of Repair Work and More Stable Operation

    TOKYO, Jun 4, 2018 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) today announced its development of a service platform that utilizes AI and other advanced digital technologies to automatically propose optimal repair work for various types of industrial machinery, and Hitachi will be commencing joint demonstrative testing in collaboration with its US subsidiary Sullair, LLC, which manufactures and sells air compressors, towards the commercial productization of the service platform. Specifically, Hitachi will verify its performance and advance the development of related applications through applying the service platform to air compressors at Sullair's own factories and those in use by Sullair customers.

    Moving forward, Hitachi will carry out joint demonstrative testing together with other partner companies in addition to Sullair in order to achieve the practical commercialization of the service platform as soon as possible; and launch a Maintenance & Repair Service with the service platform at its core, offering total support for the repair service businesses of a wide range of industrial machinery manufacturers.

    Furthermore, by integrating real-time operational data (gathered via the remote monitoring service for air compressors provided by Sullair) with the service platform, Hitachi also plans to develop technologies that will recognize early warning signs and predict breakdowns, and provide services offering preventive maintenance support to manufactures as an additional function.

    In recent years, with the increasing complexity and globalization of supply chains and the advancement of workplace automation, there are increasing needs for minimizing downtime (i.e. stoppage of operation) with regard to industrial machinery at plants, logistics facilities and construction sites. The number of skilled engineers is also declining, and there are demands for optimization and greater sophistication of repair services for products utilizing digital technologies. Until now, repair services for industrial machinery have typically involved manufacturers' service personnel travelling to the site in person (after being contacted by users upon the occurrence of a breakdown), considering and judging which parts of the machinery to repair and what repair methods to use after examining the state of the machinery themselves. Because of this, there has been an issue in that it takes certain amount of time before recovery can be achieved.

    The Hitachi Group has developed the service platform in response to this problem, through a combination of advanced digital technology and its extensive track record and expertise accumulated through many years of performing maintenance on a wide range of industrial machinery including air compressors. Based on data of breakdowns and the current state of the machinery, operational history, repair history (details of maintenance work performed including exchanges of parts and consumables, etc. and the results of such work) and the asset data, the service platform automatically suggest optimal repairs including which parts of the machinery to repair and which repair methods to use by utilizing AI technology and proprietary analytical models which combined some algorithms, in order to achieve a high complete recovery rate. For example, in the event of an air compressor stopping operation due to an increase in temperature, by having users input data (such as the state displayed on the control panel at the time of the breakdown, and how long the machine has been running for) into the service platform, it can display which part of the machine is most likely to be the cause of the breakdown, and automatically suggest optimal repair and response procedures, both to users and to the manufacturer. Furthermore, because the service platform utilizes AI technology, it is capable of learning continuously, which increases the accuracy of its proposals based on interrelationships between accumulated data, including data on machinery breakdowns, details of repairs and the results of work performed.

    By introducing the service platform, manufacturers of industrial machinery will be able to make advance preparations for repair work based on the content of suggestions made by the service platform before their service personnel head to the actual site of the breakdown, thereby minimizing the need for backtracking, even in the case of already-installed machinery not equipped with IoT devices (which cannot be monitored remotely). As a result, manufacturers will be able to simultaneously increase operational efficiency and improve the quality of their repair services, enabling them to enhance their maintenance service business operations. This will also enable users to reduce downtime due to the occurrence of machinery breakdowns and minimize lost business opportunities.

    Moving forward, Hitachi will commence to achieve the practical commercialization of the service platform as soon as possible; and launch a Maintenance & Repair Service with the service platform at its core, offering total support for the repair service businesses of industrial machinery manufacturers. Furthermore, by integrating real-time operational data collected from industrial machinery with the service platform developed this time, Hitachi also plans to provide support for manufacturers' preventive maintenance services as an additional function, by developing the service platform into a sophisticated predictive maintenance system.

    Hitachi regards this Maintenance & Repair Service as one of the solution cores of its IoT platform Lumada, and will continue to offer digital solutions covering the entire value chain-including after-sales services-to customers in the Industrial & Distribution business domain; in addition to the management support, manufacturing workplace and logistics solutions it has provided up until now.

    About Hitachi, Ltd.

    Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges with our talented team and proven experience in global markets. The company's consolidated revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3 billion). Hitachi is focusing more than ever on the Social Innovation Business, which includes power & infrastructure systems, information & telecommunication systems, construction machinery, high functional materials & components, automotive systems, healthcare and others. For more information on Hitachi, please visit the company's website at

    Hitachi Ltd Corporate Communications Tel: +81-3-3258-1111

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    BANGKOK, Jun 4, 2018 - (JCN Newswire) - Mitsubishi Motors Corporation (MMC) announced today that Mitsubishi Motors (Thailand) Co., Ltd. (MMTh), its exclusive producer and distributor in Thailand, has marked five million units vehicles produced at the facility in Laem Chabang. The landmark vehicle was a Mitsubishi Pajero Sport.

    The event was graced by Somkid Jatusripitak, Deputy Prime Minister of the Kingdom of Thailand; His Excellency Shiro Sadoshima, Ambassador Extraordinary and Plenipotentiary of Japan; Osamu Masuko, CEO of Mitsubishi Motors Corporation and BOI's Honorary Investment Advisor. Other VIP guests, business partners and employees were also in attendance.

    During his address, Somkid Jatusripitak congratulated Mitsubishi Motors for the successful collaboration between the automaker and the Thai government.

    He said, "Mitsubishi Motors Thailand's milestone today underlines the role of the automotive industry as one of Thailand's growth engines. The company's commitment to Thailand, and its leadership in sustainable practices is initiative that will help us achieve our national economic goals."

    Also speaking at the ceremony was Osamu Masuko, CEO of Mitsubishi Motors Corporation. He expressed his gratitude for the support and cooperation from the Thai government, and explained: "We have always had the confidence in Thailand's potential for domestic market growth. Its long-term policies to grow the automotive industry also a positive sign for our business."

    MMTh's facilities at Laem Chabang are the biggest outside Japan, capable of producing 424,000 vehicles a year with exports going to more than 120 countries. The output supports the company's growth in the ASEAN region as well as internationally.

    Meanwhile, Morikazu Chokki, President and CEO of Mitsubishi Motors (Thailand) Co., Ltd. said during the ceremony, "We will continue to pioneer new segments and technology. We will innovate and enhance hard and soft technology into human-centric packages, and deliver versatility, driving confidence and functionality. This forms the basis of our global tagline 'Drive your Ambition' and is our commitment to our drivers."

    Mitsubishi Motors started its operations in Thailand in 1961 and achieved its first million-unit production in 2003. The second million followed in 2010 and after just three years, MMTh hit the third million in 2013. As demand increased, the four-million mark was reached in 2015.

    Out of the five million vehicles, 3.7 million were for export markets in more than 120 countries worldwide. In 2016, Mitsubishi Motors Thailand celebrated its third-million export vehicle.

    MMTh currently operates three automobile plants in Laem Chabang. The first plant was opened in 1992, and the second in 1996, the latter focusing on production of one-ton pickup trucks as the production hub and export base.

    In 2007, Mitsubishi Motors Thailand joined the Eco Car project and invested in the third automobile plant, which started producing eco cars in 2012. MMTh also has a powertrain plant that produces engines for both domestic and export markets.

    Mitsubishi Motors Thailand currently has over 6,600 employees. To enhance its operations and leverage its role among Mitsubishi Motors group, the company also has facilities for Global Parts Logistics, a proving ground and a new training center.

    About Mitsubishi Motors

    Mitsubishi Motors Corporation is the sixth largest automaker in Japan and the sixteenth largest in the world. It is part of the Mitsubishi keiretsu, formerly the biggest industrial group in Japan, and was formed in 1970 from the automotive division of Mitsubishi Heavy Industries. From October 2016, Mitsubishi is one-third owned by Nissan, and a part of the Renault - Nissan - Mitsubishi Alliance. For more information, please visit

    Mitsubishi Motors Public Relations Department +81-3-6852-4275

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    From Investigational Studies of Lenvima and Keytruda Combination Therapy in Four Different Tumor Types

    - First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)
    - Updated results show antitumor activity with a consistent safety profile in advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC)
    - The LENVIMA/KEYTRUDA combination was recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for advanced RCC
    - Phase III trials underway in advanced RCC (NCT02811861) and advanced EC (NCT03517449)

    TOKYO, Jun 4, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), announced today that results from presentations of new data and analyses of LENVIMA (lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in four different tumor types: unresectable hepatocellular carcinoma (HCC) (Abstract #4076), squamous cell carcinoma of the head and neck (SCCHN) (Abstract #6016), advanced renal cell carcinoma (RCC) (Abstract #4560), and advanced endometrial carcinoma (EC) (Abstract #5596 and Abstract #5597). The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today.

    "The data we have observed in the combination studies of LENVIMA plus KEYTRUDA have fueled our commitment to help meet the diverse health care needs of patients living with cancer through clinical studies and research in specific tumor types that are notoriously difficult to treat and continue to have a significant need for new therapeutic options," said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. "We are pleased to share the activity observed in clinical studies of the LENVIMA plus KEYTRUDA combination, as well as rationale for the combination in advanced endometrial carcinoma through translational research."

    "With these data at ASCO, we are continuing to see encouraging overall response rates, as well as a safety profile that supports the scientific rationale of adding LENVIMA to KEYTRUDA," said Dr. Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck & Co., Inc., Kenilworth, N.J., U.S.A. "These findings add to the growing body of evidence showing the potential of this combination regimen across a number of tumor types and underscore the strategy behind our collaboration with Eisai."

    This release discusses investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

    About Eisai

    Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

    Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    Results of the the Phase II Study Demonstrated a Statistcally Significant Difference in Amyloid beta in Brain

    TOKYO, Jun 5, 2018 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. This study, a Phase II study of 70 patients, is the first study of a BACE inhibitor to show a statistically significant difference in amyloid beta in the brain while also suggesting a delay of clinical symptom decline in exploratory endpoints.

    Study 202 ( identifier NCT02322021) is a multicenter, randomized, double-blind, placebocontrolled parallel-group 18-month Phase II clinical study in patients with mild cognitive impairment (MCI) due to Alzheimer's disease, or mild to moderate dementia due to Alzheimer's disease with confirmed amyloid pathology by PET screening. Seventy patients were randomized to four treatment arms receiving elenbecestat (5, 15, or 50 mg) or placebo daily. During the study period, more than half the patients in the elenbecestat 5 mg and 15 mg arms were switched to the 50 mg arm for three months or more. The 50 mg treatment arm plus the group switched to the 50 mg arm are hereafter referred to as "50 mg total arm" (38 subjects) with a mean duration of approximately 11 months on 50 mg per day.

    Elenbecestat demonstrated acceptable safety and tolerability profile through 18 months of study drug administration. In the elenbecestat 50 mg total arm, the six most common adverse events observed were contact dermatitis, upper respiratory infection, headache, diarrhea, fall, and dermatitis. No serious adverse reactions suggestive of hepatic toxicity were observed in this study.

    In addition to the safety objectives, the study assessed AB in the brain at 18 months as measured by amyloid PET as well as efficacy in terms of clinical symptoms, which were exploratory objectives in this study. The elenbecestat 50 mg total arm demonstrated a statistically significant difference in AB levels in the brain as measured by amyloid PET compared with placebo (35 subjects participated in this longitudinal amyloid PET assessment). This is the first time in which a significant effect in AB in the brain using a BACE inhibitor was confirmed in a clinical study of patients with mild cognitive impairment (MCI) through moderate Alzheimer's dementia.

    CDR-SB (Clinical Dementia Rating Sum of Boxes) was an exploratory endpoint to assess efficacy in terms of clinical symptoms. The study showed numerically less decline in CDR-SB for the elenbecestat 50 mg total arm as compared to placebo of a potentially clinically important difference (41 subjects participated in this assessment), which was not statistically significant. Further, a similar magnitude and direction of differential in decline was observed in a post-hoc analysis of ADCOMS, Eisai's newly developed assessment scale (Alzheimer's Disease Composite Score) in the elenbecestat 50 mg total arm as compared to placebo. The study was not powered to show statistical significance compared to placebo on clinical symptoms.

    Eisai plans to present detailed results of the study at a future medical meeting.

    Elenbecestat, discovered by Eisai, has been jointly developed by Eisai and Biogen since March 2014. The two companies are currently conducting two global Phase III clinical studies (MISSION AD1/2) in early Alzheimer's disease.

    "It is highly encouraging that Study 202 confirmed elenbecestat's treatment effect in reducing amyloid in the brain and suggested a slowing of clinical decline. Eisai and Biogen will continue to work together to advance the ongoing Phase III program (MISSION AD) in order to contribute a new potential treatment option to Alzheimer's disease patients as soon as possible," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai.

    "Biogen is heartened by the safety and tolerability results of this study of elenbecestat," said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. "We remain committed to research in Alzheimer's, an area of significant unmet need with a devastating impact on those living with the disease, their families, friends, and society."

    About Elenbecestat (generic name, development code: E2609)

    Elenbecestat is an oral BACE (beta amyloid cleaving enzyme) inhibitor currently being investigated in Phase III clinical studies for Alzheimer?s disease discovered by Eisai. By inhibiting BACE, a key enzyme in the production of Aβ peptides, elenbecestat reduces Abeta production, which is thought to lead to a reduction in amyloid plaque formations caused by the aggregation of toxic oligomers and protofibrils in the brain. Currently, two global Phase III clinical studies (MISSION AD1/2) of elenbecestat in early Alzheimer?s disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD are underway. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elenbecestat, a process allowing priority reviews by the FDA for drugs deemed as having potential to treat serious conditions and tackle key unmet medical needs.

    About Study 202 ( identifier NCT02322021)

    Study 202 is a placebo-controlled, double-blind, parallel-group, randomized, dose-finding study to evaluate the safety and tolerability of elenbecestat in 70 patients with mild cognitive impairment due to Alzheimer's disease (prodromal Alzheimer's disease) and mild to moderate dementia due to Alzheimer's disease. The study enrolled patients which met the core clinical research criteria of the U.S. National Institute on Aging - Alzheimer's Association for MCI due to AD or AD dementia, with an MMSE score of 16 or higher and confirmed accumulation of Aβ by PET screening. Patients were allocated to a total of four treatment arms, three for elenbecestat (5 mg/day: 17 patients, 15 mg/day: 19 patients, 50 mg/day: 17 patients) and one for placebo (17 patients). More than half the patients in the elenbecestat 5 mg and 15 mg treatment arms had their dose increased to 50 mg/day during the 18 month treatment period. Mean duration of 50 mg total arm on 50 mg/day was 11 months. The primary objectives are safety and tolerability at 18 months. Major exploratory endpoints are the change in accumulation of Abeta as measured by amyloid PET (35 patients) and the change in dementia assessment scales including CDR-SB and ADCOMS (41 patients), at 18 months compared to baseline.

    About Eisai

    Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

    Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    Fumihiko Yoshida, Editor-in-Chief of the Journal for Peace and Nuclear Disarmament
    The cover of the Journal for Peace and Nuclear Disarmament
    A Japanese university that suffered from atomic devastation will help pave the way towards a world without nuclear weapons.

    Nagasaki, Japan, Jun 5, 2018 - (ACN Newswire) - The inaugural issue of the Journal for Peace and Nuclear Disarmament (J-PAND) was published in May by Nagasaki University's Research Center for Nuclear Weapons Abolition (RECNA).

    The English-language journal aims to provide a forum for proposing policies and other ideas that could contribute to nuclear disarmament. To encourage public debate, J-PAND is provided on an open access basis by its publisher Taylor & Francis.

    In the first edition, readers can find new ideas and perspectives on the Nuclear Weapons Ban Treaty and no-first-use of nuclear weapons.

    "As is demonstrated in North Korea's nuclear programme and the latest US Nuclear Posture Review under the Trump administration, nobody can evade this issue. By launching J-PAND, we wish to provide an academic platform for promoting nuclear disarmament," says Fumihiko Yoshida, who serves as Editor-in-Chief of the journal.

    Seventy-three years ago, an atomic bomb was dropped on Nagasaki, Japan. Located close to the hypocentre, Nagasaki Medical College was totally destroyed. Nearly 900 faculty members, students, and medical workers were killed.

    The reconstruction of the college appeared to be an impossible mission. But from the ashes of the atomic wasteland rose the renewed Nagasaki University, which has developed into a world research centre on atomic radiation.

    Determined to eliminate nuclear weapons, Nagasaki University established the Research Center for Nuclear Weapons Abolition in 2012. It was apparent that former US President Barack Obama's landmark speech in Prague in April 2009 was a source of inspiration.

    The second edition of J-PAND will be published at the end of 2018 and is expected to feature issues such as diversifying nuclear strategies and nuclear risks.

    Dr. Hibiki Yamaguchi
    Managing Editor
    Journal for Peace and Nuclear Disarmament
    Nagasaki University

    Journal information
    Journal for Peace and Nuclear Disarmament, Vol.1, Issue 1.

    Press release distributed by ResearchSEA.

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Six-month Campaign Raises Awareness about the Threat of Vehicular Cyber-Attacks

    SUNNYVALE, CA, Jun 5, 2018 - (ACN Newswire) - Trillium President and CEO David Uze is embarking tomorrow on a six-month road trip to publicize the reality of automotive cyber-attacks, commonly known as car hacking, an intrusion often done remotely using a digital device. The threat is real, and it exists today across industry sectors from cell phones to home computers to autonomous and connected vehicles.

    Trillium's mission is to provide lifecycle cybersecurity protection for vehicular data, whether for the family on vacation in their car or for the mechanisms in a military vehicle, designed to protect America's interests on the battlefield. Uze and his fellow "cyber warriors" at Trillium are committed to educating the public about their multi-layered solutions that provide real-time protection in all types of vehicles from cars to trucks to military tanks.

    Driving a Trillium-branded Tesla, Uze will criss-cross America on several road trips, talking to drivers about their vehicles as "computers on wheels" that need cyber protection; visiting universities to encourage engineering students to join the war against cyber thieves; and talking to university professors about how Trillium can support more research into effectively fighting cyber-hacking. Periodically, Uze plans to stop at American landmarks to push the message out to the American public beyond the occasional news story about ransomware or a huge cyber breach. He wants people to know that it can happen to them.

    "If you don't believe a hacker can get into your car remotely using a digital device, you could end up being sadly mistaken," said Uze. "Last month, a sheriff in Michigan had his gun stolen from his car parked in front of his home. The video taken from the home's security cameras clearly shows how it happened. The thief didn't need to touch the vehicle to access the interior." Uze's first stop is Southeast Michigan where he will visit Ann Arbor and Detroit.

    "Trillium has a growing customer base in Southeast Michigan," said Uze. "The issue of cybersecurity is recognized by vehicle makers. But we want to broadcast the Trillium message to all drivers that they can be hacked. Without cybersecure software in place, hackers can penetrate a vehicle's systems in seconds through any number of attack vectors. They can open vehicle doors and windows, but even more frightening, they can take over the vehicle's steering, steal personal information from a GPS system or shut the car down altogether. Trillium products will stop them."

    Trillium is the global leader in vehicular lifecycle cybersecurity assurance platforms. Uze and his management team see this campaign as a first step in their quest to broaden the cyber-protection conversation. For example, fleets of vehicles are vulnerable to remote hacking as are autonomous vehicles which are currently under development by both public and private companies. Trillium works with these industry sectors and with aerospace and defense companies. The Department of Homeland Security hacked into a Boeing 757 as recently as last year.

    Through its "Hack Across America" project, Trillium is doing its part to alert American drivers to hidden cybersecurity risks. For Trillium, the future is now, and speed is crucial to raising the hacking work factor thereby discouraging cyber-criminals.

    About Trillium Secure, Inc.
    The Trillium vehicular lifecycle cybersecurity assurance platform provides a multi-layered solution for hardening connected and autonomous vehicles against cyber-attack. Trillium's SecureIOT platform provides authenticated operational and threat management data from fleet vehicles that preserves privacy, confidentiality and anonymity of data while at rest and in motion. Value-added service providers rely on secure and authentic data from Trillium for digital forensics, UBI, preventive maintenance, telematics, car sharing and other services. Trillium design centers and fleet security operation sites are located in Silicon Valley, Ann Arbor, Ho Chi Minh City and Tokyo. For more information, please visit

    Trillium Secure, Inc. products and services are marketed under the Trillium, SecureGO, SecureIoT, SecureCAR, SecureIXS, SecureOTA and SecureSKYE trademarks.

    For Media Enquiries, please contact

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    HONG KONG, Jun 5, 2018 - (ACN Newswire) - Self-sovereign digital identity creation platform Blockpass has announced plans to partner with token-issuing platform and exchange BlockEx as an official distributor of the much-anticipated PASS Token, which was released on May 31st of this year.

    The BlockEx Digital Asset Exchange Platform (DAxP) manages the entire lifecycle of blockchain based digital assets, including origination, issuance, exchange, settlement and redemption. The DAxP includes a digital asset creation tool, exchange, clearing, settlement, registry and Brokerage Software.

    Blockpass is a blockchain-based identity verification application that supports user-centric digital identity creation facilitating seamless and cost-effective access to regulated blockchain services and connected devices. The fully-functioning Blockpass application supports both iOS and Android and allows users to have complete control over their identity data, allowing for greater security, protection, and user data independence. For businesses, Blockpass offers a comprehensive identity verification portal for quick and easy user onboarding.

    PASS Tokens, released on May 31st, enable Blockpass to offer shared regulatory compliance services for humans, companies, objects and devices. PASS Tokens was released in a world-first Token Distribution Event, supported by a list of distributors which now includes BlockEx. Contributors can purchase PASS tokens through Blockpass' official distributor network using the Blockpass app and a newly verified identity.

    "We're very enthusiastic about this new partnership with BlockEx as distributor of the PASS token, but also as an opportunity to expand the Blockpass user base," said Blockpass CEO Adam Vaziri. "This is one more step in growing our shared compliance and regulatory ecosystem."

    According to BlockEx CEO, Adam Leonard, "Becoming a distributor of the PASS token means we are supporting a more compliant regulated token ecosystem. It gives us the opportunity to grow and evolve with the changing landscape of the blockchain economy."

    Blockpass has announced a number of different partnerships lately, including Holdex, Myki, and Infinito Wallet. In addition, in April of this year, Blockpass announced the creation of the Blockpass Identity Lab - a pioneering research lab which will explore ways in which blockchain technology can protect personal data from online scammers and hackers.

    About Blockpass IDN
    The goal of Blockpass IDN ( is global realization of identity for the Internet of Everything. Through the use of blockchain technology and smart contracts, Blockpass is a production ready Regtech platform offering shared regulatory and compliance services for humans, businesses, objects and devices. As this identity system supports verification of humans (KYC), objects (KYO) and connected devices (KYD), it will enable the development of new applications that rely on a trusted connection between human, corporate, and device identities. Registered in Hong Kong, Blockpass IDN is a joint venture of Infinity Blockchain Labs and Chain of Things. Blockpass IDN licenses its technology from the non-profit Blockpass Foundation, registered in the Isle of Man.

    For more information and updates, please visit:
    Promotional video:

    Media contact:
    Caitlin Betts
    T: +852 9733 4935

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Thailand, Jun 5, 2018 - (JCN Newswire) - Mitsubishi Motors Corporation (MMC) announced today that Mitsubishi Motors (Thailand) Co., Ltd. (MMTh), its exclusive producer and distributor in Thailand, has officially opened a new training facility, the Education Academy, in Pathum Thani. This is another example of the extensive effort the company is making to pursue the very best customer service.

    The official opening ceremony was held with Don Samitakasettrin, Lamlukka District Chief Officer and other related parties along with Osamu Masuko, CEO of Mitsubishi Motors Corporation.

    Osamu Masuko said "Mitsubishi Motors has always been focusing on Thailand. The Education Academy reflects our commitment here in Thailand at the same time as the country is shifting towards the economy."

    The official inauguration of Education Academy was a day after the 5 million-unit production celebration at Mitsubishi Motors Thailand production facility in Laem Chabang.
    "The Education Academy will play a vital role in providing our people with knowledge and skills enablement to prepare them for the new values we want to deliver to our drivers." Masuko added.

    The Education Academy project started in September 2017. Today the 2-story building with around 8,700 sqm function area stands tall on more than 17,700 sqm Mitsubishi Motors Thailand premise in Lamlukka, Phathum Thani.

    Morikazu Chokki, President and CEO, Mitsubishi Motors (Thailand) Co., Ltd. said during the opening ceremony: "Education Academy will contribute significantly in our 'software' development with the focus on sales and aftersales services enhancement."

    Currently, Education Academy serves 100 - 150 people daily including Service Advisors, Technicians, Part Staff, Sales Consultants, Customer Relations Officers, and Mitsubishi Motors Thailand staff.

    "What the staff will be taught and be trained here is not just about technical proficiency. They will be valued as a staff with ambition to explore. So that they can empower our drivers to explore new things and progress in life." Chokki concluded.

    About Mitsubishi Motors

    Mitsubishi Motors Corporation is the sixth largest automaker in Japan and the sixteenth largest in the world. It is part of the Mitsubishi keiretsu, formerly the biggest industrial group in Japan, and was formed in 1970 from the automotive division of Mitsubishi Heavy Industries. From October 2016, Mitsubishi is one-third owned by Nissan, and a part of the Renault - Nissan - Mitsubishi Alliance. For more information, please visit

    Public Relations Department +81-3-6852-4275

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    Figure 1: Diagram of Blockchain Asset Service
    Figure 2: Diagram of measures to attract customers to stores and facilities using this service
    Figure 3: Example of usage status
    Bolsters marketing activities with data analysis and conversion of user point records to "assets"

    TOKYO, Jun 6, 2018 - (JCN Newswire) - Fujitsu today announced the launch of Fujitsu Intelligent Society Solution Blockchain Asset Service, a cloud service that provides retail mechanisms, such as digital points, stamps and coupons, which can be used for a limited time in specified areas including tourist sites, markets, and shopping centers, using blockchain technology. Sales of the service begin today in Japan. With this service, users can collect digital points or stamps by reading QR codes located in specific areas with smart devices, and then exchange them for coupons and other benefits that can be used in stores and shopping centers within the specified area. In addition, collection and usage data for the points, stamps, and coupons, which are recorded on the blockchain distributed ledger, can be linked with user information for analysis. By connecting events and promotions held in tourist areas or shopping centers with this service, users (customers) can improve the rate at which they attract customers and increase their willingness to buy. At the same time, they can also more effectively set strategies for regional revitalization, based on the activity patterns of users seen in the analysis results, and on such factors as the use of the coupons and other benefits. This service will be exhibited at Interop Tokyo 2018, held in Makuhari Messe (Chiba, Japan), June 13-15.


    In recent years, there have been high expectations for events designed to attract tourists, whose numbers have been trending upward, including tourists from outside Japan. At the same time, there is a demand for the implementation of rapid sales strategies to respond to the desires and interests of various tourists, aimed at economic revitalization in rural and tourist areas. To revitalize specific regions and areas, Fujitsu has been conducting field trials of digital "stamp rally" promotions using blockchain technology, working with organizations including Odakyu Electric Railway Co., Ltd., the Shizuoka branch of Nippon Telegraph and Telephone West Corporation, Taiwan FamilyMart Co., Ltd., and the city of Chiba in partnership with The Chiba Bank. In these field trials, Fujitsu supported its customers' marketing activities by hosting hands-on events linked to the "stamp rally" promotion, as well as connecting and analyzing limited attribute data on user activity, such as the data on which stamps they collected.
    Figure 1: Diagram of Blockchain Asset Service

    Features of the Blockchain Asset Service

    1. Useable as a measure for attracting customers to stores or events

    Customers who implement this service can connect this service with applications they develop, such as those relating to specific events, and can use the asset management functionality to record and manage the details of the digital points, stamps, or coupons that have been distributed, as well as records of transactions using them. Customers can also use the service to define the details of the points, stamps, or coupons, as well as the area and time period in which they can be used. With a smart device application connected to this, service users can convert points or stamps, collected using QR codes placed in specified areas, into coupons or other benefits that can be used in specified stores or shopping centers. This can lead to improved customer attraction rates of special events at tourist sites or promotional campaigns for shopping centers, as well as an increased willingness to buy. This service is available to customers in the form of an API, making it easy for customers to connect it to the applications they develop. Customers can utilize this service safely, securely, and quickly, even without having a dedicated ICT environment or expertise in blockchain technology.
    Figure 2: Diagram of measures to attract customers to stores and facilities using this service

    2. Enables marketing that combines user data with transaction information recorded in blockchain

    Transaction information about how users take advantage of digital points recorded on the distributed ledger of a blockchain is linked with user data, limited to information such as age and sex that do not identify individuals, which is collected through login connection functionality. This linkage enables a detailed analysis of user interests and activities, which can be used to attract customers and set sales strategy going forward. In addition, using the system's operations management function, which enables customers to check the distribution and usage status of coupons, it is possible to visualize the circulation of points and stamps, and the usage status of coupons.
    Figure 3: Example of usage status

    Total sales of 100 units by the end of fiscal 2020 (Fujitsu's fiscal year ends March 31).

    About Fujitsu Ltd

    Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 155,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.5 trillion yen (US$40 billion) for the fiscal year ended March 31, 2017. For more information, please see

    * Please see this press release, with images, at:

    Fujitsu Limited Public and Investor Relations Tel: +81-3-3215-5259 URL:

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    TOKYO, Jun 6, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States.

    Lemborexant is currently being studied for the potential treatment of multiple sleep disorders. Positive topline results from these Phase I studies as well as a Phase III study (SUNRISE 1), which compared lemborexant to placebo in patients with a sleep disorder and included the first-ever head-to-head superiority comparison versus zolpidem extended release (zolpidem ER) as a secondary endpoint, were previously announced.

    Phase I Study 108 - "Auditory Awakening Threshold to Evaluate Ability to Awaken After Administration of Lemborexant Versus Zolpidem" (Poster # 097)

    Study 108 met its primary endpoint resulting in a statistically significant difference in postural stability with both doses of lemborexant compared to zolpidem ER in the middle of the night. The mean changes from baseline in body sway, a measure of postural stability, were -1.1 units for placebo, 5.8 units for lemborexant 5 mg, 8.1 units for lemborexant 10 mg, and 20.4 units for zolpidem ER 6.25 mg; (p
    Healthy volunteers 55 years and older (n=56) were administered treatments at bedtime, and body sway was assessed upon awakening participants after approximately four hours in bed. A 7 unit increase from baseline was defined as a clinically meaningful increase in body sway, as benchmarked to the effect of alcohol on the same measure of postural stability.(1) Zolpidem ER increased body sway at a magnitude almost three times greater than the increase in body sway associated with a blood alcohol content (BAC 0.05 percent) near the legal driving limit. Lemborexant 5 mg did not result in a clinically meaningful increase in body sway, while lemborexant 10 mg increased body sway to just above the clinically meaningful threshold.

    The next morning, shortly after the end of eight hours in bed, unlike zolpidem ER, neither dose of lemborexant had statistically significant residual effects on this measure of postural stability as compared to placebo. The mean changes from baseline in body sway were -2.2 units for placebo, 0.4 units for lemborexant 5 mg, -0.4 units for lemborexant 10 mg, and 5.0 units for zolpidem ER 6.25 mg (p=NS [not significant] for both doses of lemborexant vs. placebo, p=0.01 for zolpidem ER vs. placebo).

    "Postural instability is thought to be the single best predictor of falls.(2) Significant unmet need exists for a treatment that can help people awaken in the night or the next morning without this type of impairment," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "If approved, lemborexant, our investigational sleep/wake regulation agent, may have the potential to reduce the risk of postural instability."

    In this Phase I study, there were no serious adverse events (AE). Headache was the only AE observed in two or more subjects taking lemborexant. The only AE that occurred in more than one subject in any treatment period was nasopharyngitis, which occurred in the placebo treatment period. Rates of treatment-emergent AEs were low and of mild or moderate severity.

    Two subjects discontinued due to an AE. There were no AEs of somnolence.

    A secondary study objective was to evaluate the effects of lemborexant 5 mg and 10 mg on the auditory awakening threshold (AAT), a measure of the ability to be awakened by an external stimulus at approximately four hours post-dose, compared to zolpidem ER and placebo. A clinically meaningful increase in AAT was pre-specified as an 8-decibel (dB) change from baseline. Neither dose of lemborexant had a statistically significant difference relative to placebo or zolpidem ER on the ability to awaken to an external stimulus. The mean treatment differences compared to placebo were 1.7 dB for lemborexant 5 mg, -0.9 dB for lemborexant 10 mg, and 7.2 dB for zolpidem ER 6.25 mg (p=NS). Of the subjects who completed all four treatments, eight subjects taking zolpidem ER did not awaken to the loudest tone of 105 dB, compared with four subjects in each of the other treatment groups (placebo, n=42; lemborexant 5 mg, n=47; lemborexant 10 mg, n=50; and zolpidem ER, n=50). Varying n's were due to either the subject already being awake thus no AAT was administered, or a technical issue with the AAT equipment.

    "By acting on the orexin neurotransmitter system, which regulates wakefulness, lemborexant appears to affect sleep and wake by dampening excessive wakefulness and does not appear to impede the ability to awaken to external stimuli," said Russell Rosenberg, PhD, D. ABSM, a Principal Investigator in lemborexant studies and former Chairman of the Board of the National Sleep Foundation. "As the largest study conducted to date evaluating postural stability and auditory awakening threshold in the middle of the night, these data about the effects of lemborexant on measures of balance and responsiveness to external stimuli are encouraging with respect to addressing current unmet needs in the treatment of sleep disorders."

    In addition, return to sleep latency was evaluated as an exploratory endpoint and both doses of lemborexant had faster return to sleep after being awakened in the middle of the night compared to placebo. The mean treatment differences compared to placebo were -22.5 minutes for lemborexant 5 mg, -28.7 minutes for lemborexant 10 mg, and -21.0 minutes for zolpidem ER (p
    These results support findings from SUNRISE 1, a recently completed Phase III study of lemborexant (5 mg and 10 mg) versus placebo, including a superiority comparison to zolpidem ER as a secondary endpoint. The study met endpoints of time to sleep onset and sleep maintenance as measured by polysomnography, as well as body sway upon awakening, when compared to placebo and zolpidem ER. In this study, lemborexant had rates of discontinuation due to AEs comparable to placebo, with the most common AEs in the lemborexant arms being headache and somnolence.

    Phase I Study 106 - "Results From an On-Road Driving Performance Study in Non-elderly and Elderly Healthy Subjects with Dual Orexin Receptor Antagonist Lemborexant" (Poster # 099)
    Study 106 evaluated next-morning effects of lemborexant compared with placebo, with zopiclone included as a positive control, by measuring adult and elderly participants' (n=48) driving performance via an on-road driving test. The primary endpoint was to evaluate difference from placebo of standard deviation of lateral position (SDLP), an index of weaving, during an on-road driving test on the mornings following the first and last dose of drug in each treatment period. Drug-placebo differences in SDLP >2.4 cm are considered to reflect clinically meaningful driving impairment, as benchmarked against a BAC of 0.05 percent.

    Lemborexant 2.5, 5 and 10 mg showed no statistically significant impairment of driving performance, as measured by mean changes in SDLP, after either single (Day 2) or multiple (Day 9) dose administration compared to placebo, meeting the study's primary endpoint. In contrast, zopiclone 7.5 mg significantly increased mean SDLP as compared to placebo. The mean drug-placebo changes in SDLP (in centimeters) compared to placebo for Day 2 were 0.02 cm for lemborexant 2.5 mg, 0.23 cm for lemborexant 5 mg, 0.73 cm for lemborexant 10 mg, and 2.04 cm for zopiclone 7.5 mg. For Day 9, the mean drug-placebo changes in SDLP were 0.48 cm for lemborexant 2.5 mg, 0.36 cm for lemborexant 5 mg, 0.74 cm for lemborexant 10 mg, and 1.88 cm for zopiclone 7.5 mg. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP were all below 2.4 cm for all three doses of lemborexant on Days 2 and 9, indicating that there was not clinically meaningful driving impairment. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP for zopiclone was greater than 2.4 cm on Days 2 and 9, demonstrating assay sensitivity.

    No drives were stopped before completion in the lemborexant treatment groups, whereas, three drives out of a total of 384 (0.8 percent) were terminated before scheduled completion, all after the use of zopiclone. No serious or severe AEs were reported in any treatment group. There were no treatment-related AEs leading to withdrawal from the study. The most common AEs observed in the lemborexant treatment groups were somnolence, headache, and dry mouth. Somnolence was reported more frequently with lemborexant 10 mg than lemborexant 2.5 mg and 5 mg.

    "Sleep medications should not only improve the ability to sleep through the night, but also allow patients to awaken in the middle of the night, if needed, and to function upon awakening," said Marcelo Bigal, MD, PhD, Chief Medical Officer, Purdue Pharma. "We are pleased to share these study results and are committed to exploring the value of lemborexant in specific unmet needs of patients with sleep disorders."

    Discovered by Eisai, lemborexant is a sleep/wake regulation agent being jointly developed by Eisai and Purdue. Through research and development on lemborexant, Eisai and Purdue are striving to improve the quality of life of, and further contribute to, sleep disorder patients and their families.

    About lemborexant

    Lemborexant (development code: E2006), a dual orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule compound that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with sleep disorders, it is possible that the orexin system that regulates sleep and wakefulness is not functioning normally. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully counteract inappropriate wakefulness and facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission. Therefore, Eisai and Purdue have been developing lemborexant as a treatment for multiple sleep disorders.

    In addition, a Phase II clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.

    About Study 1083

    Study 108 was a randomized, double-blind, four-period, Phase I crossover study that evaluated the effect of lemborexant on postural stability, auditory awakening threshold and cognitive performance in healthy volunteers age 55 years and older; 120 subjects were screened, 63 randomized, and 56 completed all four treatment groups. Participants were administered a single dose of placebo, lemborexant 5 mg, lemborexant 10 mg, or zolpidem ER 6.25 mg, and had eight-hour polysomnograms at baseline and at each single-dose treatment. If not already awake, subjects were awakened, preferentially from stage non-REM 2 in the middle of the night (between four and four and a half hours post-bedtime/post-dose). At bedside, body sway with eyes closed was measured in units of 1/3o angle of arc for 60 seconds using an ataxiameter device. Increases from baseline of greater than or equal to 7 units were pre-specified as clinically meaningful, benchmarked to effect of alcohol at 0.5g/kg. At eight hours post-dose, body sway was assessed in the same manner.

    The study also evaluated the effects of lemborexant on the AAT. Subjects slept with insert earphones, an auditory stimulus apparatus that produced 1000Hz tones for three seconds at 15-second intervals. The starting dB level was 15, increasing five dB to a maximum of 105dB, until the subject stated, "I'm awake." The awakening threshold was the dB level one level below the response.

    About Study 1064

    Study 106 was a randomized, double-blind, placebo- and active-controlled, four-period, Phase I crossover study evaluated the effect of lemborexant in 48 healthy adult and elderly volunteers to evaluate on-road driving performance. Participants (n=24 elderly and n=24 non-elderly) were treated at bedtime with two out of three dose levels of lemborexant (2.5, 5 or 10 mg) and placebo for eight consecutive days, and zopiclone 7.5 mg as an active control on days one and eight only, with placebo given for the six days in between. Standardized one-hour on-road driving tests on the second and ninth days were started approximately nine hours post-dose.

    About Sleep Disorders

    Population studies show that sleep disorders affect many more people worldwide than previously thought. Insomnia disorder is characterized by difficulty falling sleep, staying asleep or both, despite an adequate opportunity to sleep, that can lead to daytime consequences such as fatigue, difficulty concentrating and irritability.(4),(5) Insomnia disorder is the most common sleep disorder, with persistent insomnia symptoms experienced by approximately 10 percent of the adult population.(5),(6)

    Sleeping well is essential for good health, including brain health. Poor sleep is associated with a wide range of health consequences, including an increased risk of hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke and dementia, as well as adverse effects on mood and behavior.(7),(8)

    Experimental studies in animals and humans provide evidence of associations between sleep and disease risk factors, diseases and mortality.(5),(9) Studies suggest an optimal sleep duration between seven and eight hours.(5),(9) Women are 1.4 times more likely than men to suffer from insomnia.(10)

    Older adults also have higher prevalence of insomnia; aging is often accompanied by changes in sleep patterns, including disrupted sleep, frequent waking and early waking, that can lead to less sleep time.)11)

    About Purdue Pharma L.P.

    Purdue Pharma L.P. is a privately held pharmaceutical company headquartered in Stamford, Conn. Purdue Pharma is part of a network of independent associated companies dedicated to providing patients and providers with innovative medicines. The company's leadership and employees are committed to serving healthcare professionals, patients and caregivers by providing quality products and educational resources that make a positive impact on healthcare - and on lives.

    For more information, please visit

    (1) Wesnes KA, Garatt C, Wickens M, Gudgoen A, Oliver S. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol. 2000;49:110-17.
    (2) Blaszczyk JW, et al. Ageing and postural stability. Stud Phys Cult Tourism. 2006;13(S):11-14.
    (3) Eisai Inc. Crossover study to evaluate the effect of lemborexant versus placebo and zolpidem on postural stability, auditory awakening threshold, and cognitive performance in healthy subjects 55 years and older (E2006-A001-108).
    (4) Eisai Inc. Study to evaluate the effect of lemborexant versus placebo on driving performance in healthy adult and elderly subjects (E2006-E044-106).
    (5) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
    (6) Ohayon MM, et al. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 002;6(2):97-111.
    (7) Institute of Medicine. Sleep disorders and sleep deprivation: An unmet public health problem. Washington, DC: National Academies Press. 2006.
    (8) Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244-1250.
    (9) Trenell MI, et al. Sleep and metabolic control: waking to a problem? Clin Exp Pharmacol Physiol. 2007;34:1-9.
    (10) Zhang B, Wing, YK. Sex differences in insomnia: a meta-analysis. Sleep. 2006;29(1):85-93.
    (11) Ohayon MM, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27:1255-1273.

    About Eisai

    Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

    Purdue Pharma L.P. Danielle Lewis Tel: +1-203-588-7653 Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    Toyota City, Japan, Jun 6, 2018 - (JCN Newswire) - Seven-Eleven Japan Co., Ltd. (Seven-Eleven) and ToyotaMotor Corporation (Toyota) announce today details of a joint project to reduce CO2 emissions. Seven-Eleven and Toyota entered into a basic agreement in August 2017 regarding considerations toward energy conservation and carbon dioxide emission reduction in store distribution and operation. Toyota has been investigating the use of newly developed fuel cell trucks and fuel cell generators, and the project will be implemented in stages starting in 2019.

    The project aims to introduce technologies and systems developed by Toyota in Seven-Eleven store operation and distribution, reducing CO2 emissions. Stationary fuel cell generators (FC generators) and rechargeable batteries will be introduced at stores, managed centrally by building energy management systems (BEMS), raising the proportion of renewable energy and electric power derived from hydrogen used. A newly developed small fuel cell truck (small FC truck) will be introduced in the distribution process, aiming to achieve zero emissions of substances of concern including CO2.

    The Seven & i Group is currently addressing five key issues. Regarding non wasteful usage of products, ingredients and energy, Seven & i is seeking to expand renewable energy use in line with the objectives of the Sustainable Development Goals (SDGs) adopted by the United Nations in 2015. Specifically, the Group plans to increase renewable energy use in stores to 20 percent and reduce CO2 emissions by 27 percent compared to FY 2013 by 2030. Seven-Eleven is taking measures to reduce CO2 emissions throughout its entire supply chain to meet its goals, focusing on renewable energy.

    On December 7, 2017, Seven-Eleven opened the environmentally, user friendly Seven-Eleven Chiyoda Nibancho Store as a flagship of these initiatives. The second such store, the Seven-Eleven Sagamihara Hashimotodai Itchome Store, opened on May 22, 2018, with renewable energy accounting for 46 percent of the store's electric power usage. Toyota technologies and systems that use hydrogen will be introduced in stores and distribution sites, with next generation stores further using renewable energy. Two small FC trucks are intended to be introduced within the Tokyo metropolitan region in approximately spring 2019, and operations next generation stores are expected to commence in approximately autumn 2019.

    Toyota announced the Toyota Environmental Challenge 2050 in October 2015, which aims to assist in developing a sustainable society. Accordingly, Toyota is taking active measures to reduce CO2 emissions by promoting efficient energy use and alternative energy use, to address global environmental issues such as global warming, resource scarcity, and energy challenges. The current joint project aims to reduce CO2 emissions and conserve energy in Seven-Eleven store operation and distribution, and intends to support the accumulation and verification of new technologies and knowledge such as small FC trucks and FC generators.

    About Toyota

    Toyota Motor Corporation (TMC) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 29 countries, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries under the brands Toyota, Lexus, Daihatsu and Hino. For more information, please visit

    Public Affairs Division Global Communications Department Toyota Motor Corporation Tel: +81-3-3817-9926

    Copyright 2018 JCN Newswire. All rights reserved.

    0 0

    The integration of technologies will unlock impact data from grassroots communities

    HONG KONG, Jun 6, 2018 - (ACN Newswire) - iO2 Foundation ("iO2") has signed a Memorandum of Understanding (MoU) with the ixo Foundation ("ixo"), to create a strategic partnership. The collaboration includes the integration of technologies and business model strategies, to enhance data collection for impact investment on blockchain, ultimately revolutionising the social finance infrastructure.

    Dr. Tat Lam, Co-Founder and Chief Social Scientist at iO2, says: "The iO2 team has spent the last three years developing AI for data collection and impact measurement in grassroots communities, with the aim of closing the last-mile gap collecting high quality and trusted data in developing regions. We are very glad to be part of the efforts to support the ixo community's global impact investment projects on the blockchain, aspiring to revolutionise the social finance infrastructure and realise the UN's 2030 Sustainable Development Goals (SDG)."

    ixo is the new operating system for the Impact Economy, using blockchain and W3C decentralised web standards, to enable anyone to collect, measure, evaluate, value, and tokenize verified impact data. By partnering with the iO2 Foundation, data collected from projects and beneficiaries will become cleaner, higher-quality, and faster-velocity at scale, thus enabling much easier, cheaper, immediate and more reliable impact measurement.

    Dr. Lam, who has personally worked in over 200 rural villages in mainland China to pilot technology application in social development, continues: "ixo is the pioneering technology for developing impact financing mechanisms on the blockchain; the ixo Foundation steers significant impact investment projects around the world. We are delighted to establish this strategic partnership, on shared passion to develop blockchain solutions to allow impact investors in the ixo Community to verify data for capital deployment and accelerate the pace to unlock impact investment opportunities for global sustainable goals."

    Dr. Shaun Conway, President of the ixo Foundation Council said, "We are excited about bringing together the capabilities of ixo and iO2, to make these technologies and tools meaningful to people."

    On June 7 2018, Dr. Tat Lam will be participating in the Smart Impact Bonds Hackathon in Switzerland, co-sponsored by The UBS Optimus Foundation & ixo Foundation, to generate three to five technical white papers on smart contract-based social finance innovation, that will help set the path towards the future of impact financing.

    About iO2
    iO2, or Impact Oxygen, is a Hong Kong-based Decentralized Autonomous Organization for crowd-enabled impact investment and social finance structuring on the blockchain, underpinned by iO2 Token that incentivises grassroots communities to provide trusted data for impact measurement and accountability. Since 2015, the iO2 team has successfully developed and executed over a dozen social impact projects in China via its service platform "Shanzhai City" ( and AI platform "Impact Learning" (, and now are engaging blockchain-based projects in Myanmar, Laos, Thailand and Brazil working solving issues ranging from refugee aid to reducing infant mortality.

    For more information, please visit and join the iO2 Telegram group at

    About ixo Foundation
    The ixo Foundation is a non-profit open-source software development foundation building the ixo Blockchain for Impact. The world is starting to realize how important it is to really count what matters, for people and the planet. With ixo, all measurable changes that have an impact can now be transformed into Verified Impact Data with crypto-economic Proof of Impact, which enables anyone to value what counts for sustainable social, environmental and economic development. Trusted Impact data grows investments into impacts and optimizes the results, assisted by machine learning and intelligent oracles. The ixo protocol generates Impact Tokens that are traded through decentralised impact exchanges. These valuable digital assets will create new marketplaces for the Impact Economy. With ixo, everyone has the power to deliver, evaluate or invest in Impact. Together we can create the world we want and achieve the Global Goals for Sustainable Development by the year 2030.

    Join the ixo Telegram group ( to share your thoughts & have your questions answered.

    Find iO2 Foundation on:

    Find ixo Foundation on:
    Twitter: @ixo_impact

    For investment community, please contact:

    Howie Chan
    Head of Growth
    Tel: +852 6693 3379

    For media enquiries, please contact:

    New Smile Strategic IR & PR Consultancy
    Kristy Tsang
    Tel: +852 9107 6485

    Copyright 2018 ACN Newswire. All rights reserved.

    0 0

    Main theme for this year "Leadership in Times of Change"

    HONG KONG, Jun 6, 2018 - (ACN Newswire) - The Hong Kong Institute of Directors ("HKIoD") has announced that the 18th annual "Directors Of The Year Awards 2018" is accepting nominations starting today. This year, its main theme is "Leadership in Times of Change", which aims to recognise the leaders who uphold good corporate governance, lead their teams to the forefront of the digital era and effectively face the opportunities and challenges in the "new normal" economy, amidst the challenging times.

    Mr Henry Lai, Chairman of the Council of HKIoD, said, "In the lead-up to the 18th Directors of the Year Awards organised by HKIoD, we have witnessed the collision of emerging and legacy technologies creating and reshaping the operational model and rules of the commercial world. A parallel reform of corporate governance is becoming a key to success in the business world. An example can be seen in risk management, an important duty in good corporate governance. While the security of the corporate cloud network is part of risk management, so the board of directors of a company should regard the risk from this upgrade as its own duty and should not rely solely on digital and technological experts. Leaders who hold fast to corporate governance as they strive to cope with the new economy should be commended. How to drive further company expansion with new approaches and new insights is a topic deserving consideration for the new generation leaders. We hope the Awardees of Directors Of The Year Awards 2018 can bring a fresh perspective on corporate governance to these new leaders."

    Mr William Lo, Chairman of the Awards Organising Committee, said, "In the current digital era, technologies are evolving, advancing almost every second and have changed the old patterns of society starting long ago. Such a disruption has definitely presented big challenges to the leaders in their governance. Standing still is no longer an option for leaders in heading the company or they will be eventually ousted by the march of time. The reason for the Organising Committee to set this year's theme for the Awards as 'Leadership in Times of Change' is to establish standards and provide incentives for Hong Kong's business sector to review the whole operation and governance system."

    Dr Carlye Tsui, CEO of HKIoD, said, "Nurturing successful leaders is not something which can be accomplished in a single day. Therefore, we have been keeping pace with the market trends and have designed specific courses and training for directors. We hope to encourage them to adhere to their corporate governance principles despite the disruption of the new economy and at the same time come up with creative ideas to align with the current operation models."

    Nomination for the Awards will close on 31 July 2018. The Panel of Judges consists of outstanding business leaders, professionals and regulators in Hong Kong. Director Of The Year Awards 2018 recognises excellence in the following categories:

    Company Categories / Director Categories:
    1. Listed Companies (SEHK - Hang Seng Indexes Constituents) / 1. Executive Directors
    2. Listed Companies (SEHK - Non-Hang Seng Indexes Constituents) / 2. Non-Executive Directors
    3. Private Companies / 3. Boards
    4. Statutory/Non-profit-distributing Organisations

    The selection criteria for winners in the Individual Director Categories include their effectiveness in performing strategic corporate business functions, contribution to board effectiveness, contribution towards managing change, risk and succession, leadership and other attributes and qualities, including continuing professional development for directors, business ethics and other outstanding achievements. As for the Collective Board Categories, judging criteria include board composition, skill mix and competencies of directors, effectiveness in performing strategic corporate business functions, development and implementation of strategic plans and monitoring of performance, managing compliance and accountability, managing change, risk and succession, development of the board, including continuing professional development for directors, effectiveness of board committees and business ethics as well as any other achievements.

    The Awards nomination form and related information are available on The Hong Kong Institute of Directors website at

    About Directors Of The Year Awards
    First launched in 2001, Directors Of The Year Awards were the first ever such Awards organised in Asia. The project has now become an annual project of impact in the community. The objectives are to recognise directors and board of directors for outstanding director practices and corporate governance, to publicise the significance of good corporate governance and to promote awareness of good corporate governance and director professionalism in Hong Kong. Nominations are open to the public. As good corporate governance is vital to all types of organisations, and professional director practices are encouraged from directors in all board roles, the Awards recognise excellence in categories by company types, including listed companies, private companies and statutory/non-profit-distributing organisations, and categories by roles, including Executive Directors, Non-Executive Directors and Boards. For more details on the previous years' Awards, please visit

    About The Hong Kong Institute of Directors
    The Hong Kong Institute of Directors is Hong Kong's premier body representing directors to foster the long-term success of companies through advocacy and standards-setting in corporate governance and professional development for directors. A non-profit-distributing organisation with membership consisting of directors from listed and non-listed companies, HKIoD is committed to providing directors with educational programmes and information service and establishing an influential voice in representing directors. With international perspectives and a multi-cultural environment, HKIoD conducts business in biliteracy and trilingualism. Website:

    Media Enquiries:
    Strategic Public Relations Group Limited
    Eveline Wan +852 2864 4822
    Brenda Chan +852 2114 4396
    Chak Yau +852 2114 4395

    Directors Of The Year Awards 2018 Enquiries:
    The Hong Kong Institute of Directors
    Odessa SO +852 2889 4988
    Moni Ching +852 2889 1414

    Copyright 2018 ACN Newswire. All rights reserved.

older | 1 | .... | 266 | 267 | (Page 268) | 269 | 270 | .... | 320 | newer